Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 170-182

  Tweedie, David ^a   Rachmany, Lital ^b   Rubovitch, Vardit ^a   Lehrmann, Elin ^a   Zhang, Yongqing ^a   Becker, Kevin G ^a   Perez, Evelyn ^a   Miller, Jonathan ^c   Hoffer, Barry J ^c   Greig, Nigel H ^a   Pick, Chaim G ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Exendin 4; Gene expression; Glucagon like peptide 1; Mild traumatic brain injury (mTBI); Novel object recognition

Indexed keywords

EXENDIN 4;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HIPPOCAMPUS; MALE; MENTAL PERFORMANCE; MICROARRAY ANALYSIS; MOUSE; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RECOGNITION; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN INJURIES; COGNITION; COMPUTATIONAL BIOLOGY; DNA, COMPLEMENTARY; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; HIPPOCAMPUS; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEUROPROTECTIVE AGENTS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECOGNITION (PSYCHOLOGY); RNA; SIGNAL TRANSDUCTION; VENOMS;

EID: 84868458245     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.001     Document Type: Article

References (84)

1. Andrews-Zwilling Y., Bien-Ly N., Xu Q., Li G., Bernardo A., Yeon Yoon S., Zwilling D., Xue Yan T., Chen L., Huang Y. Apolipoprotein E4 causes age- and tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 2010, 30:13707-13717.
2. Azevedo F.A., Carvalho L.R., Grinberg L.T., Farfel J.M., Ferretti R.E., Leite R.E., Jacob Filho W., Lent R., Herculano-Houzel S. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J. Comp. Neurol. 2009, 513:532-541.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
4. Bak A.M., Egefjord L., Gejl M., Steffensen C., Stecher C.W., Smidt K., Brock B., Rungby J. Targeting amyloid-beta by glucagon-like peptide-1 (GLP-1) in Alzheimer's disease and diabetes. Expert Opin. Ther. Targets 2011, 10:1153-1162.
5. Baratz R., Tweedie D., Rubovitch V., Luo W., Yoon J.S., Hoffer B.J., Greig N.H., Pick C.G. Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J. Neurochem. 2011, 118:1032-1042.
6. Belsham D.D., Fick L.J., Dalvi P.S., Centeno M.L., Chalmers J.A., Lee P.K., Wang Y., Drucker D.J., Koletar M.M. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J. 2009, 23:4256-4265.
7. Bennin D.A., Don A.S., Brake T., McKenzie J.L., Rosenbaum H., Ortiz L., DePaoli-Roach A.A., Horne M.C. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B' subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J. Biol. Chem. 2002, 277:27449-27467.
8. Bertilsson G., Patrone C., Zachrisson O., Andersson A., Dannaeus K., Heidrich J., Kortesmaa J., Mercer A., Nielsen E., Rönnholm H., Wikström L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 2008, 86:326-338.
9. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest. 2012, 122:1339-1353. 10.1172/JCI57256.
10. Bonislawski D.P., Schwarzbach E.P., Cohen A.S. Brain injury impairs dentate gyrus inhibitory efficacy. Neurobiol. Dis. 2007, 25:163-169.
11. Costanza A., Weber K., Gandy S., Bouras C., Hof P.R., Giannakopoulos P., Canuto A. Contact sport-related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates. Neuropathol. Appl. Neurobiol. 2011, 37:570-584.
12. Currais A., Hortobágyi T., Soriano S. The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer's disease. Aging (Albany NY) 2009, 1:363-371.
13. Dail W.G., Feeney D.M., Murray H.M., Linn R.T., Boyeson M.G. Responses to cortical injury: II. widespread depression of the activity of an enzyme in cortex remote from a focal injury. Brain Res. 1981, 211:79-89.
14. Darsalia V., Mansouri S., Ortsäter H., Olverling A., Nozadze N., Kappe C., Iverfeldt K., Tracy L.M., Grankvist N., Sjöholm Å., Patrone C. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin. Sci. 2012, 122:473-483.
15. De Kruijk J.R., Twijnstra A., Meerhoff S., Leffers P. Management of mild traumatic brain injury: lack of consensus in Europe. Brain Inj. 2001, 15:117-123.
16. DeKosky S.T., Ikonomovic M.D., Gandy S. Traumatic brain injury-football, warfare, and long-term effects. N. Engl. J. Med. 2010, 363:1293-1296.
17. Dixon C.E., Lyeth B.G., Povlishock J.T., Findling R.L., Hamm R.J., Marmarou A., Young H.F., Hayes R.L. A fluid percussion model of experimental brain injury in the rat. J. Neurosurg. 1987, 67:110-119.
18. Dixon C.E., Clifton G.L., Lighthall J.W., Yaghmai A.A., Hayes R.L. A controlled cortical impact model of traumatic brain injury in the rat. J. Neurosci. Methods 1991, 39:253-262.
19. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. for the DURATION-1 Study Group.
20. Edut S., Rubovitch V., Schreiber S., Pick C.G. The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI). Psychopharmacology (Berl) 2010, 214:877-889.
21. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
22. Faul M., Xu L., Wald M.M., Coronado V.G. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006 2010, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta (GA).
23. Feeney D.M., Boyeson M.G., Linn R.T., Murray H.M., Dail W.G. Responses to cortical injury: I. methodology and local effects of contusions in the rat. Brain Res. 1981, 211:67-77.
24. Fernandoa R.N., Eleuteria B., Abdelhadya S., Nussenzweigb A., Andänga M., Ernforsa P. Cell cycle restriction by histone H2AX limits proliferation of adult neural stem cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5837-5842.
25. Gibson C.J., Meyer R.C., Hamm R.J. Traumatic brain injury and the effects of diazepam, diltiazem, and MK-801 on GABA-A receptor subunit expression in rat hippocampus. J. Biomed. Sci. 2010, 17:38.
26. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 1995, 62:130-134.
27. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7:2294-2300.
28. Goldstein L.E., Fisher A.M., Tagge C.A., Zhang X.L., Velisek L., Sullivan J.A., Upreti C., Kracht J.M., Ericsson M., Wojnarowicz M.W., Goletiani C.J., Maglakelidze G.M., Casey N., Moncaster J.A., Minaeva O., Moir R.D., Nowinski C.J., Stern R.A., Cantu R.C., Geiling J., Blusztajn J.K., Wolozin B.L., Ikezu T., Stein T.D., Budson A.E., Kowall N.W., Chargin D., Sharon A., Saman S., Hall G.F., Moss W.C., Cleveland R.O., Tanzi R.E., Stanton P.K., McKee A.C. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci. Transl. Med. 2012, 4:134ra60.
29. Griffioen K.J., Wan R., Okun E., Wang X., Lovett-Barr M.R., Li Y., Mughal M.R., Mendelowitz D., Mattson M.P. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc. Res. 2011, 89:72-78.
30. Guzowski J.F., McNaughton B.L., Barnes C.A., Worley P.F. Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nat. Neurosci. 1999, 2:1120-1124.
31. Hamilton A., Patterson S., Porter D., Gault V.A., Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 2011, 89:481-489.
32. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149:4059-4068.
33. Hoge C.W., McGurk D., Thomas J.L., Cox A.L., Engel C.C., Castro C.A. Mild traumatic brain injury in U.S. soldiers returning from Iraq. N. Engl. J. Med. 2008, 358:453-463.
34. Hölscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam. Horm. 2010, 84:331-354.
35. Holst J.J., Burcelin R., Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr. Med. Res. Opin. 2011, 27:547-558.
36. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikström L. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 2011, 650:249-255.
37. Israelsson C., Wang Y., Kylberg A., Pick C.G., Hoffer B.J., Ebendal T. Closed head injury in a mouse model results in molecular changes indicating inflammatory responses. J. Neurotrauma 2009, 26:1307-1314.
38. Johnson V.E., Stewart W., Smith D.H. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012, 22:142-149.
39. Jordan-Sciutto K.L., Morgan K., Bowser R. Increased Cyclin G1 immunoreactivity during Alzheimer's disease. J. Alzheimers Dis. 1999, 1:409-417.
40. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
41. Kim-Chung L.T., Hosaka T., Yoshida M., Harada N., Sakaue H., Sakai T., Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem. Biophys. Res. Commun. 2009, 390:613-618.
42. Kiraly M., Kiraly S.J. Traumatic brain injury and delayed sequelae: a review-traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementia. Scientific World Journal 2007, 7:1768-1776.
43. Lahiri D.K., Sambamurti K., Bennett D.A. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease. Neurobiol. Aging 2004, 25:651-660.
44. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1285-1290.
45. Li, H., Lee C.H., Yoo K.Y., Choi J.H., Park O.K., Yan B.C., Byun K., Lee B., Hwang I.K., Won M.H. Chronic treatment of exendin-4 affects cell proliferation and neuroblast differentiation in the adult mouse hippocampal dentate gyrus. Neurosci. Lett. 2010, 486:38-42.
46. Li Y., Duffy K.B., Ottinger M.A., Ray B., Bailey J.A., Holloway H.W., Tweedie D., Perry T., Mattson M.P., Kapogiannis D., Sambamurti K., Lahiri D.K., Greig N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1205-1219.
47. Li Y., Tweedie D., Mattson M.P., Holloway H.W., Greig N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 2010, 113:1621-1631.
48. Li Y., Chigurupati S., Holloway H.W., Mughal M., Tweedie D., Bruestle D.A., Mattson M.P., Wang Y., Harvey B.K., Ray B., Lahiri D.K., Greig N.H. Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One 2012, 7(2):e32008.
49. Lighthall J.W. Controlled cortical impact: a new experimental brain injury model. J. Neurotrauma 1988, 5:1-15.
50. Lighthall J.W., Goshgarian H.G., Pinderski C.R. Characterization of axonal injury produced by controlled cortical impact. J. Neurotrauma 1990, 7:65-76.
51. Liu X., Wang Q., Haydar T.F., Bordey A. Nonsynaptic GABA signaling in postnatal subventricular zone controls proliferation of GFAP-expressing progenitors. Nat. Neurosci. 2005, 8:1179-1187.
52. Marklund N., Hillered L. Animal modeling of traumatic brain injury in preclinical drug development: where do we go from here?. Br. J. Pharmacol. 2011, 164:1207-1229.
53. Marmarou A., Foda M.A., van den Brink W., Campbell J., Kita H., Demetriadou K. A new model of diffuse brain injury in rats. Part I: pathophysiology and biomechanics. J. Neurosurg. 1994, 80:291-300.
54. Martin B., Golden E., Carlson O.D., Pistell P., Zhou J., Kim W., Frank B.P., Thomas S., Chadwick W.A., Greig N.H., Bates G.P., Sathasivam K., Bernier M., Maudsley S., Mattson M.P., Egan J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 2009, 58:318-328.
55. Martínez-Gac L., Marqués M., García Z., Campanero M.R., Carrera A.C. Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol. Cell. Biol. 2004, 24:2181-2189.
56. McClean P.L., Parthsarathy V., Faivre E., Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
57. Mendez C.V., Hurley R.A., Lassonde M., Zhang L., Taber K.H. Mild traumatic brain injury: neuroimaging of sports-related concussion. J. Neuropsychiatry Clin. Neurosci. 2005, 17:297-303.
58. Messier C. Object recognition in mice: improvement of memory by glucose. Neurobiol. Learn. Mem. 1997, 67:172-175.
59. Milman A., Rosenberg A., Weizman R., Pick C.G. Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice. J. Neurotrauma 2005, 22:1003-1010.
60. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
61. Morita N., Kiryu S., Kiyama H. p53-independent cyclin G expression in a group of mature neurons and its enhanced expression during nerve regeneration. J. Neurosci. 1996, 16:5961-5966.
62. O'Shea D., Gunn I., Chen X., Bloom S., Herbert J. A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport 1996, 7:830-832.
63. Pan W., Kastin A.J., Rigai T., McLay R., Pick C.G. Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice. Exp. Brain Res. 2003, 149:195-199.
64. Perry T., Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol. Sci. 2003, 24:377-383.
65. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
66. Perry T., Holloway H.W., Weerasuriya A., Mouton P.R., Duffy K., Mattison J.A., Greig N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 2007, 203:293-301.
67. Rachmany L., Tweedie D., Li Y., Rubovitch V., Holloway H.W., Miller J., Hoffer B.J., Greig N.H., Pick C.J. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr). 2012, [Electronic publication ahead of print]. 10.1007/s11357-012-9464-0.
68. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2007, 22:659-661. 10.1096/fj.07-9574LS.
69. Russo I., Amornphimoltham P., Weigert R., Barlati S., Bosetti F. Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. Cell Cycle 2011, 10:2568-2573.
70. Russo I., Barlati S., Bosetti F. Effects of neuroinflammation on the regenerative capacity of brain stem cells. J. Neurochem. 2011, 116:947-956.
71. Sadaka F., Veremakis C. Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review. Brain Inj. 2012, 26:899-908.
72. Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011, 11:775-787.
73. Salcedo I., Tweedie D., Li Y., Greig N.H. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br. J. Pharmacol. 2012, 166:1586-1599. 10.1111/j.1476-5381.2012.01971.x.
74. 2. J. Neurosurg. 1979, 51:18-26.
75. Sullivan H.G., Martinez J., Becker D.P., Miller J.D., Griffith R., Wist A.O. Fluid-percussion model of mechanical brain injury in the cat. J. Neurosurg. 1976, 45:521-534.
76. Sultana R., Butterfield D.A. Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment. Neurochem. Res. 2007, 32:655-662.
77. Tashlykov V., Katz Y., Gazit V., Zohar O., Schreiber S., Pick C.G. Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice. Brain Res. 2007, 1130:197-205.
78. Tashlykov V., Katz Y., Volkov A., Gazit V., Schreiber S., Zohar O., Pick C.G. Minimal traumatic brain injury induce apoptotic cell death in mice. J. Mol. Neurosci. 2009, 37:16-24.
79. Tweedie D., Milman A., Holloway H.W., Li Y., Harvey B.K., Shen H., Pistell P.J., Lahiri D.K., Hoffer B.J., Wang Y., Pick C.G., Greig N.H. Apoptotic and behavioral sequelae of mild brain trauma in mice. J. Neurosci. Res. 2007, 85:805-815.
80. Uryu K., Laurer H., McIntosh T., Praticò D., Martinez D., Leight S., Lee V.M., Trojanowski J.Q. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 2002, 22:446-454.
81. Uryu K., Giasson B.I., Longhi L., Martinez D., Murray I., Conte V., Nakamura M., Saatman K., Talbot K., Horiguchi T., McIntosh T., Lee V.M., Trojanowski J.Q. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp. Neurol. 2003, 184:214-224.
82. van Praag H., Schinder A.F., Christie B.R., Toni N., Palmer T.D., Gage F.H. Functional neurogenesis in the adult hippocampus. Nature 2002, 415:1030-1034.
83. Zhong N., Weisgraber K.H. Understanding the basis for the association of apoE4 with Alzheimer's disease: opening the door for therapeutic approaches. Curr. Alzheimer Res. 2009, 6:415-418.
84. Zohar O., Schreiber S., Getslev V., Schwartz J.P., Mullins P.G., Pick C.G. Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice. Neuroscience 2003, 118:949-955.